Mission

ICAN, International Cancer Advocacy Network, is a Platinum-rated 501(c)(3) charitable organization specializing in direct navigation of Stage IV cancer patients, offering second opinion referrals, molecular profiling/comprehensive biomarker testing connections, clinical trials matching services, and early access/compassionate use matching services. At year-end, ICAN was ranked fourth in the nation by Great Nonprofits in its Top-Rated Nonprofit Campaign (Cancer) in terms of highest rated and most rated cancer organizations. ICAN services have reached 97 countries. ICAN has three goals in assisting patients and their care partners: 1) optimize survival; 2) emphasize quality of life; and 3) embark on "no regrets" journey with the confidence that key issues will not be overlooked. The Exon 20 Group is a multi-stakeholder global coalition consisting of patients, care partners, family members, thoracic oncologists and community oncologists, scientists, molecular pathologists, molecular profiling laboratory leadership, and pharma, biotech, and CRO leadership. The Exon 20 Group is a special biomarker-specific organization under the auspices of ICAN, focusing on pan-tumor EGFR exon 20 insertion mutations and HER2 exon 20 insertion mutations which are diagnosed in 25 plus cancer types and affect patients from infancy, childhood through the nineties. The patient population features predominantly never smokers, women, and those of Asian heritage. The Exon 20 Group offers second opinion referrals, clinical trials matching and expanded access matching services, and emphasizes molecular testing at relevant pivot points. The Group provides an Angel Buddy Program with peer-to-peer counseling, oncology nursing services, virtual meetings, and 20 plus social media sites strictly for patients and their care partners. The group's Exon 20 International Research Consortium fosters collaborative projects between physician-scientists and leading research laboratories. The work of the Ex 20 IRC and the impact of ICAN's Exon 20 Group Campaign for the Cure are likely to impact other cancer types as well. https://exon20group.org The MET Crusaders is a multi-stakeholder international support organization which handles MET exon 14, MET amplified, and MET over-expression patients in the U.S. and around the world. https://metcrusaders.org The Biomarker Collaborative is an international multi-stakeholder coalition of biomarker groups pan-hematological cancers and pan-solid tumors. https://biomarkercollaborative.org James Creeden, MD, PhD, Razelle Kurzrock, MD, and Eric Thompson, PhD are Honorary Chairs. ICAN's biomarker-specific group, The PD-L1 Amplifieds, https://pdl1amplifieds.org is geared to patients with PD-L1 amplification (CD274 positive) which is found only by molecular profiling laboratories that deploy NGS, next-generation sequencing. One can be PD-L1 zero by IHC or PD-L1 low by IHC (immunohistochemistry) and nonetheless be PD-L1 amplified and perhaps can do well on checkpoint blockade. Razelle Kurzrock, MD is the Honorary Chair of the PD-L1 Amplifieds. The NRG1Energizers under the ICAN umbrella provides patient services to NRG1 fusion positive lung, pancreatic, cholangiocarcinoma patients (as well as patients in other tumor types). Alison Schram, MD of Memorial Sloan Kettering Cancer Center is the Honorary Chair of the NRG1 Energizers. ICAN and the organizations under its umbrella specialize in protocol review, informed consent review, and clinical trials accrual and retention. Just to clarify, our NTEE codes are E01, G01, G30, and H30. We have never been a private T22 foundation, so that is an IRS error.